Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Nephrology

Experimental Treatments and Research

At a Glance

For Hypomagnesemia 7, care currently focuses on replacing magnesium and managing heart problems; SGLT2 inhibitors and mTOR-targeting drugs remain experimental, with evidence limited to small observations or laboratory models. Patients can contribute through registries and approved studies.

Because Hypomagnesemia 7 (ADKH-RRAGD) was only recently discovered and has been identified in a small number of people worldwide, treatment today is primarily symptomatic [1]. This means that instead of fixing the underlying cellular issue, doctors focus on replacing the minerals your kidneys lose and managing heart function with standard medications [2]. However, researchers are actively looking for ways to treat the cellular cause of the disease.

The Problem at the Cellular Level

As you may have read on earlier pages, the RRAGD variant alters cellular signaling, leading to overactive or misplaced signaling called constitutive mTORC1 signaling [1]. This constant signal is like a light switch that won’t turn off, disrupting how cells in your heart and kidneys manage energy and minerals [3].

Experimental Approaches in Patients

A small number of patients have participated in observational experiences of existing medications to see if they might help.

  • SGLT2 Inhibitors (e.g., dapagliflozin): These are common medications for diabetes and heart failure. In a small observational case series of six patients with the T97P variant, dapagliflozin slightly increased blood magnesium levels [1]. However, it also made hypokalemia (low potassium) worse [1][2]. Because of this “trade-off” and risks like volume depletion, genital infections, and euglycemic ketoacidosis, these drugs are not a standard part of treatment for RRAGD. You should not seek out or start these medications outside of a specialist-supervised plan or a properly governed clinical study.

Laboratory Frontiers: Targeted Therapy

The most advanced research is currently happening in laboratories using zebrafish and iPSCs (human “stem cells” grown in a dish from patient samples).

  • mTOR Inhibitors (Rapamycin and Torin1): Since the disease is associated with an “overactive” mTORC1 signal, researchers have tested drugs that block that signal in experimental models. In zebrafish models, the drug rapamycin was able to reverse heart weakness and improve the heart’s pumping function [4]. In human cell models, another inhibitor called Torin1 was able to “reset” the signaling pathway to a more normal state [5].
  • Why these aren’t used yet: While these results are promising, these findings are strictly preclinical. There is no demonstrated clinical benefit of these drugs in people with RRAGD disease. mTOR inhibitors are powerful medications often used in organ transplants; they have significant side effects, including affecting the immune system and kidney function [1]. These drugs should not be pursued outside an appropriate, ethics-reviewed clinical study and specialist consultation.

How to Stay Involved

Because this condition is so rare, every patient’s data is vital to the scientific community. You can help advance research by:

  1. Joining a Registry: Large-scale registries like the European Rare Kidney Disease Reference Network (ERKReg) or the UK National Registry of Rare Kidney Diseases (RaDaR) collect data to help scientists spot patterns in rare diseases [6][7].
  2. Searching for Clinical Trials: You can search databases such as ClinicalTrials.gov or your national equivalent for active, approved studies relevant to RRAGD.
  3. Connecting with Academic Centers: Major research hospitals (such as the Mayo Clinic) sometimes have programs for “Undiagnosed and Rare Diseases” that use advanced sequencing to study new variants [8]. Your care team can help you connect with these.

Before participating in any research, make sure you understand the consent process, how your privacy is protected, and that research participation is voluntary and may not benefit you personally. By participating, you help build the foundation for future “targeted” therapies.

Common questions in this guide

What treatment is available now for Hypomagnesemia 7?
Current care is mainly supportive: clinicians replace magnesium and other electrolytes lost through the kidneys and use standard medicines when heart function is affected. These measures manage the effects of the condition but do not correct the RRAGD-related cellular signaling problem.
Are SGLT2 inhibitors a proven treatment for Hypomagnesemia 7?
No. In a small observational series involving the T97P variant, dapagliflozin slightly increased blood magnesium but worsened low potassium and can cause problems such as dehydration, genital infections, and ketoacidosis. It should only be considered under specialist supervision or in a properly governed clinical study.
Could rapamycin or Torin1 be used to treat RRAGD disease?
Not as routine treatment. Rapamycin improved heart pumping in zebrafish, and Torin1 reset abnormal signaling in human cells, but these findings are preclinical and have not shown clinical benefit in people with RRAGD disease. Both should be considered only within appropriate research oversight and specialist consultation.
Has my specific RRAGD variant been studied?
Your genetics or specialty team can check whether your specific RRAGD variant has been studied in patient-derived cells, zebrafish, or another model. Results from a different variant may not predict how your variant behaves or whether a treatment will help.
How can I take part in Hypomagnesemia 7 research?
You may be able to join a rare kidney disease registry or biobank, search ClinicalTrials.gov or a national trial database, or ask an academic medical center about research programs. Before enrolling, review the consent process, privacy protections, risks, and the possibility that participation may not benefit you personally.

Get notified when new evidence is published on hypomagnesemia 7, renal, with or without dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives.

    Adella A, Jouret F, Madariaga L, et al.

    Kidney international reports 2025; (10(10)):3640-3655 doi:10.1016/j.ekir.2025.07.035.

    PMID: 41141537
  2. 2

    RRAGD-Associated Autosomal Dominant Kidney Hypomagnesemia with Cardiomyopathy: A Review on the Clinical Manifestations and Therapeutic Options.

    Trepiccione F, Sambri I, Ruggiero B, et al.

    Kidney & blood pressure research 2024; (49(1)):637-645 doi:10.1159/000539889.

    PMID: 38901414
  3. 3

    RagD auto-activating mutations impair MiT/TFE activity in kidney tubulopathy and cardiomyopathy syndrome.

    Sambri I, Ferniani M, Campostrini G, et al.

    Nature communications 2023; (14(1)):2775 doi:10.1038/s41467-023-38428-2.

    PMID: 37188688
  4. 4

    RRAGD variants cause cardiac dysfunction in a zebrafish model.

    Adella A, Tengku F, Arjona FJ, et al.

    American journal of physiology. Heart and circulatory physiology 2024; (327(5)):H1187-H1197 doi:10.1152/ajpheart.00705.2023.

    PMID: 39331021
  5. 5

    RRAGD p.(Ser76Leu) Variant Causes Dysregulated Expression of Muscle Development and Cytoskeleton Genes in Cardiomyocytes.

    Adella A, van Katwijk SB, Leermakers PA, et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2026; (40(12)):e72070 doi:10.1096/fj.202501099RR.

    PMID: 42329298
  6. 6

    The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results.

    Bassanese G, Wlodkowski T, Servais A, et al.

    Orphanet journal of rare diseases 2021; (16(1)):251 doi:10.1186/s13023-021-01872-8.

    PMID: 34078418
  7. 7

    Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort.

    Wong K, Pitcher D, Braddon F, et al.

    Kidney international reports 2024; (9(7)):2067-2083 doi:10.1016/j.ekir.2024.04.062.

    PMID: 39081723
  8. 8

    Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases.

    Wilke MVMB, Klee EW, Dhamija R, et al.

    Orphanet journal of rare diseases 2024; (19(1)):216 doi:10.1186/s13023-024-03213-x.

    PMID: 38790019

This page is for informational purposes only and does not constitute medical advice. Do not start an SGLT2 inhibitor or mTOR inhibitor for Hypomagnesemia 7 outside specialist-supervised care or an appropriately approved clinical study.